U.S. Markets closed

IDEAYA Biosciences, Inc. (IDYA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.84+0.91 (+4.15%)
At close: 4:00PM EDT
22.84 0.00 (0.00%)
After hours: 04:00PM EDT

IDEAYA Biosciences, Inc.

7000 Shoreline Court
Suite 350
South San Francisco, CA 94080
United States
650 443 6209
http://www.ideayabio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees69

Key Executives

NameTitlePayExercisedYear Born
Mr. Yujiro S. HataCo-Founder, CEO, Pres & Director711.33kN/A1974
Mr. Paul A. StoneSr. VP, CFO & Principal Accounting Officer508.44kN/A1964
Mr. Jason S. Throne J.D., Esq.Sr. VP, Gen. Counsel & Company Sec.425.56kN/A1972
Mr. Jeffrey HagerCo-Founder & Member of the Scientific Advisory BoardN/AN/A1964
Mr. Michael P. DillonSr. VP, Chief Scientific Officer & Head of ResearchN/AN/A1967
Ms. Julie PatelVP of HRN/AN/AN/A
Dr. Mark Lackner Ph.D.Sr. VP and Head of Biology & Translational SciencesN/AN/A1967
Dr. Paul A. Barsanti Ph.D.Sr. VP & Head of Drug DiscoveryN/AN/AN/A
Dr. Matthew Maurer M.D.VP and Head of Clinical Oncology & Medical AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

IDEAYA Biosciences, Inc.’s ISS Governance QualityScore as of June 30, 2021 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 9; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.